Based on the recent earnings call, Biogen has shown strong financial performance, with a significant increase in earnings per share and total revenue growth. The company's key products, TECFIDERA, ELOCTATE, and ALPROLIX, have all demonstrated substantial revenue growth. Additionally, the company has a strong focus on research and development, with plans to advance their Alzheimer's programs and build their pipeline through business development.

Based on this information, it is recommended to take an 'overweight' investment stance on Biogen. The company's strong financial performance and strategic focus on innovation and product development indicate a positive outlook for future growth and success. It is expected that the company's revenues will continue to grow, driven by their key products and potential new launches such as OCREVUS and SPINRAZA. Moreover, the company's focus on cost management and shareholder value, including a share repurchase program, further supports a positive investment outlook.

Overall, Biogen's recent earnings call provides a compelling case for an 'overweight' investment stance, with potential for strong financial performance and growth in the coming years.